Recent News

• 03.14.2025 - Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
• 03.13.2025 - Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
• 03.13.2025 - Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
• 02.28.2025 - Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology
• 02.06.2025 - Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
• 01.28.2025 - Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
• 01.28.2025 - Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
• 12.31.2024 - Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Recent Filings

• 03.14.2025 - EX-99.1 EX-99.1
• 03.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.13.2025 - EX-99.1 EX-99.1
• 02.28.2025 - EX-99.1 EX-99.1
• 02.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.06.2025 - EX-99.1 EX-99.1
• 02.04.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]